Add like
Add dislike
Add to saved papers

Long-term results of conservative treatment in Perthes' disease.

Background. Legg-Calvé-Perthes disease, due to its frequency and impact on hip function, is an important orthopedic issue. The goal of this research was to assess long-term outcome after conservative treatment in Perthes' disease. Material and methods. We studied 123 patients (135 hips), 105 males and 18 females, average follow-up 19.5 years (range 10-34), average age at onset 6.4 years. Conservative treatment involved non-weight bearing, abduction casts, orthoses and rehabilitation. The average treatment duration was 2.9 years. The range of hip motion, pelvic stability, limb length, pain, limping and physical activity were estimated. The patients were classified according to Catterall's criteria and age of onset. In x-rays the risk factors, Wiberg angle, and acetabulum-head index were measured. Outcome was assessed according to Mose and Stulberg, and arthritic changes were noted. Results. At follow-up there was full physical activity in 50 cases (40.7%). Limping was observed in 38 patients (30%), limb shortening in 27 (22%). The range of motion was limited in 37 hips (27%), and 13 hips were unstable (9.6%). There was a good Mose outcome in 36 hips (26.7%), fair in 70 (51.8%), and poor in 29 (21.5%). By Stulberg's classification, 35 hips were in class I (25.9%), 49 in class II (36.3%), 31 in class III (23%), 11 in class IV (8.1%), and 9 in class V (6.7%). Arthrotic changes were noted in 51 hips (37.8%). Conclusions. Twenty years after onset only 25% of the evaluated hips were normal. This suggests low effectiveness of treatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app